This variant was also associated with a decreased odds of coronary heart disease events (17), the effect of which was consistent with IL6R blockade from infusions of tocilizumab in patients with rheumatoid arthritis studied in randomized trials. The gene discussed is IL6R; the disease is coronary artery disorder.